• EZ Cap Cy5 Firefly Luciferase mRNA: Precision Tracking & Tra

  2026-05-13

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA advances mRNA delivery research with 5-moUTP modification, Cap1 capping, and Cy5 dual-mode tracking—bridging bioluminescence, fluorescence, and immune modulation for next-generation assay development.

• Saquinavir: Applied HIV Protease Inhibitor Workflows & Insig

  2026-05-13

  Saquinavir remains a gold-standard HIV protease inhibitor, driving reproducible antiviral and permeability research. This article distills advanced workflows, troubleshooting, and the latest biomimetic modeling innovations to empower both virology and translational oncology labs.

• Targeting Pancreatic Fibrosis via MFGE8-ANXA1-SMAD2/3 Modula

  2026-05-12

  This study demonstrates that umbilical cord-derived mesenchymal stem cells and their extracellular vesicles can attenuate pancreatic fibrosis in chronic pancreatitis by regulating the MFGE8-ANXA1-SMAD2/3 signaling axis. The work provides mechanistic insight and novel therapeutic strategies for antifibrotic intervention in digestive disorder research.

• Optimizing Apoptosis Detection with One-step TUNEL Cy5 Kit

  2026-05-12

  This article delivers a scenario-driven, evidence-based guide to overcoming common laboratory challenges in apoptosis detection using the One-step TUNEL Cy5 Apoptosis Detection Kit (SKU K1135). By anchoring protocol decisions and data interpretation to validated best practices, researchers can enhance reproducibility and quantitative rigor in programmed cell death studies across diverse models.

• Optimizing Cell Assays with EZ Cap™ Cy5 Firefly Luciferase m

  2026-05-11

  This scenario-driven article explores how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) addresses persistent challenges in cell viability and transfection assays. Readers learn how Cap1 capping, 5-moUTP modifications, and Cy5 labeling enhance reproducibility, sensitivity, and workflow safety. Practical guidance and peer-reviewed data support the selection of R1010 for robust, dual-modality assay development.

• In Situ TIL Therapy via Local mRNA Delivery: Technical Advan

  2026-05-11

  This study introduces a novel in situ tumor-infiltrating lymphocyte (TIL) therapy using lipid nanoparticle-mediated delivery of mRNA encoding a membrane-anchored anti-CD3 scFv, enabling polyclonal T cell expansion directly within the tumor microenvironment. The approach addresses key limitations of traditional TIL therapy, offering streamlined tumor-specific immune activation and potential synergy with immune checkpoint inhibitors.

• Self-Microemulsifying System Boosts Luteolin Bioavailability

  2026-05-10

  This study introduces a luteolin-loaded self-microemulsifying drug delivery system (Luteolin-SME) that significantly enhances luteolin's oral bioavailability by inhibiting P-glycoprotein-mediated efflux. The findings highlight a robust strategy to overcome intestinal absorption barriers for poorly soluble bioactive compounds, offering new directions for pharmaceutical formulation and translational research.

• Reelin–Apoer2–Src Signaling: Essential for Ketamine’s Antide

  2026-05-09

  This study reveals that intact Reelin–Apoer2–Src kinase signaling is indispensable for the synaptic and behavioral effects of ketamine in mouse models. By clarifying why some individuals do not respond to ketamine, the work provides a mechanistic foundation for future research targeting antidepressant non-responsiveness.

• SU6656 Src Tyrosine Kinases Inhibitor: Innovations in hiPSC-

  2026-05-08

  Explore how SU6656, a selective Src tyrosine kinases inhibitor, is revolutionizing hiPSC-derived platelet engineering and radiotherapy research. This article uncovers the latest protocol optimizations and evidence-based strategies for maximizing polyploidization and functional platelet yield.

• Chloramphenicol (SKU A2512): Practical Solutions for Lab Ass

  2026-05-08

  Discover how Chloramphenicol (SKU A2512) addresses persistent laboratory challenges in cell viability and plasmid selection. This evidence-based article guides life science researchers through real-world scenarios, offering data-driven insights and validated protocol recommendations for reproducibility and assay optimization.

• Practical Guide: Cy5 maleimide (non-sulfonated) for Protein

  2026-05-07

  Cy5 maleimide (non-sulfonated) enables selective fluorescent labeling of proteins and peptides through cysteine residues, supporting applications in imaging, tracking, and assay development. It is best suited for workflows requiring site-specific conjugation via thiol groups in biomolecules, but is not appropriate where aqueous solubility or non-thiol labeling is needed.

• PR-619 Protocols: Practical Guide to DUB Inhibition in Cell

  2026-05-07

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for broad-spectrum inhibition of cysteine-dependent DUBs in cell-based research. It is best suited for studies dissecting ubiquitination pathways, autophagy, and disease models where non-proteasomal DUB activity is central. Not recommended where selective DUB targeting or direct proteasome inhibition is required.

• Foretinib (GSK1363089): Precision Multikinase Inhibition in

  2026-05-06

  This thought-leadership article explores the mechanistic underpinnings and translational research strategies associated with Foretinib (GSK1363089), an advanced ATP-competitive multikinase inhibitor. Grounded in recent methodological advances and comparative literature, the piece provides actionable insights for designing robust tumor growth inhibition and metastasis assays, contextualizes Foretinib’s place in the evolving landscape of anti-cancer drug evaluation, and advances the discussion beyond conventional product pages with evidence-based, future-oriented guidance.

• Capsazepine: Synthetic TRPV1 Ion Channel Antagonist Profile

  2026-05-06

  Capsazepine is a synthetic TRPV1 ion channel antagonist with nanomolar potency, widely used to dissect nociception and apoptosis mechanisms. Its selective inhibition of capsaicin-induced responses makes it a gold standard for TRPV1 channel function research. The compound also sensitizes colon cancer cells to TRAIL-induced apoptosis, but is limited by poor water solubility and in vivo applicability.

• Integrating ARCA Cy5 EGFP mRNA (5-moUTP) into Advanced mRNA

  2026-05-05

  Discover how ARCA Cy5 EGFP mRNA (5-moUTP), a 5-methoxyuridine modified mRNA, enables robust, quantitative, and immune-evasive analysis of mRNA delivery and localization in mammalian cells. This article uniquely bridges practical protocol guidance with deeper strategy for translational mRNA research.

11735 records 1/783 page Next 12345 下5页 Last page